These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8521744)

  • 1. A comparative study between teicoplanin alone and flucloxacillin, plus or minus fusidic acid, in the treatment of serious infections caused by methicillin-susceptible gram-positive bacteria.
    Mehtar S; Drabu Y; Wilson AP; Grüneberg RN
    Chemotherapy; 1995; 41(5):412-9. PubMed ID: 8521744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teicoplanin versus flucloxacillin in the treatment of infection following burns.
    Steer JA; Papini RP; Wilson AP; McGrouther DA; Parkhouse N
    J Antimicrob Chemother; 1997 Mar; 39(3):383-92. PubMed ID: 9096188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus.
    Guenthner SH; Wenzel RP
    Antimicrob Agents Chemother; 1984 Aug; 26(2):268-9. PubMed ID: 6237606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of vancomycin, teicoplanin and fusidic acid as prophylactic agents in prevention of vascular graft infection: an experimental study in rat.
    Yasim A; Gul M; Atahan E; Ciragil P; Aral M; Ergun Y
    Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):274-9. PubMed ID: 16360328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of penicillin G, flucloxacillin, cefazolin, fusidic acid, vancomycin, rifampicin and fosfomycin in muscular infections in mice due to Staphylococcus aureus.
    Haag R
    Infection; 1986; 14(1):38-43. PubMed ID: 3957435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases.
    Wilson AP; Gaya H
    J Antimicrob Chemother; 1996 Sep; 38(3):507-21. PubMed ID: 8889725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections.
    Bibler MR; Frame PT; Hagler DN; Bode RB; Staneck JL; Thamlikitkul V; Harris JE; Haregewoin A; Bullock WE
    Antimicrob Agents Chemother; 1987 Feb; 31(2):207-12. PubMed ID: 2952062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of vancomycin and teicoplanin alone or in combination with fusidic acid or amikacin against methicillin-resistant staphylococci.
    Roussel-Delvallez M; Wallet F; Barbiery P; Courcol RJ
    J Chemother; 1997 Feb; 9(1):5-8. PubMed ID: 9106011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methicillin resistance in Staphylococcus aureus with particular reference to Victorian strains.
    Harvey K; Pavillard R
    Med J Aust; 1982 May; 1(11):465-7. PubMed ID: 7048040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antistaphylococcal activity of teicoplanin in Riyadh, Saudi Arabia.
    Shibl AM; Ishag AH; Durgham SM
    APMIS Suppl; 1988; 3():68-70. PubMed ID: 2972301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of serious gram-positive infections with teicoplanin.
    Davies AJ; Stone JM; Synott M
    Drugs Exp Clin Res; 1989; 15(1):29-31. PubMed ID: 2526010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.
    Calain P; Krause KH; Vaudaux P; Auckenthaler R; Lew D; Waldvogel F; Hirschel B
    J Infect Dis; 1987 Feb; 155(2):187-91. PubMed ID: 2949024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of the combination of teicoplanin or flucloxacillin with netilmicin in the treatment of Staphylococcus aureus bacteraemia.
    Degener JE; Vogel M; Michel MF; Mutsaers MM; Hop WC
    J Antimicrob Chemother; 1989 Jun; 23(6):899-904. PubMed ID: 2527224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro kinetics of the activity of fusidic acid and fluoroquinolones combinations against staphylococci according to methicillin-resistance phenotype. Implications for the treatment of osteoarticular infections].
    Reynaud AE; Espaze EP; Coste-Burel M; Richet H
    Pathol Biol (Paris); 1992 May; 40(5):466-70. PubMed ID: 1495828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teicoplanin monotherapy of serious infections caused by gram-positive bacteria: a re-evaluation of patients with endocarditis or Staphylococcus aureus bacteraemia from a European open trial.
    Davey PG; Williams AH
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():43-50. PubMed ID: 1829076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Staphylococcal infection in the newborn: teicoplanin therapy].
    Fanos V; Khoory BJ; Danieli D; Padovani EM
    Pediatr Med Chir; 1993; 15(6):579-82. PubMed ID: 8197017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro modelling of the bactericidal activity of teicoplanin versus flucloxacillin as used in surgical prophylaxis, against Staphylococcus aureus.
    Steer JA; Hill GB; Robbins MJ; Newton JC; Wilson AP
    J Antimicrob Chemother; 1997 Apr; 39(4):477-81. PubMed ID: 9145820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teicoplanin compared to flucloxacillin for antibiotic treatment of neutropenic patients.
    Smith CL; Milliken S; Powles R; Da Costa F; Gore M; Benjamin S; Talbot D; Ellis L; Large J; Jameson B
    Br J Haematol; 1990 Dec; 76 Suppl 2():6-9. PubMed ID: 2149055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection.
    Schrenzel J; Harbarth S; Schockmel G; Genné D; Bregenzer T; Flueckiger U; Petignat C; Jacobs F; Francioli P; Zimmerli W; Lew DP;
    Clin Infect Dis; 2004 Nov; 39(9):1285-92. PubMed ID: 15494904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.